Nkarta (NKTX) Return on Sales (2019 - 2020)

Nkarta's (NKTX) quarterly Return on Sales came in at 1371.43% in Q4 2020, up 707.08% quarter-over-quarter from 225.91% in Q3 2020.

Nkarta (NKTX) Return on Sales (2019 - 2020) Analysis & Trends

Nkarta's Return on Sales history runs 2 years deep, the most recent figure standing at 1371.43% for Q4 2020.

On a quarterly basis, Return on Sales changed N/A year-over-year to 1371.43% in Q4 2020; TTM through Dec 2020 was 1371.43%, a N/A change from a year earlier, with the FY2019 full-year figure at 2.05%, changed N/A from the prior year.
Return on Sales rose to 1371.43% in Q4 2020 per NKTX's latest filing, from 225.91% in the prior quarter.
Across five years, Return on Sales topped out at 1371.43% in Q4 2020 and bottomed at 225.91% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.00%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	0.00%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Nkarta	170.79 Mn	170.79 Mn	-	-

Download Data